Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrice Rodien

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Journal of Clinical Medicine|January 21, 2022
A Tear Metabolomic Profile Showing Increased Ornithine Decarboxylase Activity and Spermine Synthesis in Thyroid-Associated OrbitopathyBenjamin Billiet, Juan Manuel Chao de la Barca, Marc Ferré, et al.
European Journal of Endocrinology|August 20, 2013
Surgery for 'asymptomatic' mild primary hyperparathyroidism improves some clinical symptoms postoperativelyClaire Blanchard, Muriel Mathonnet, Frédéric Sebag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Lancet (London, England)|October 19, 2004
Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardationEdith C H Friesema, Annette Grueters, Heike Biebermann, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2020
Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for EndocrinologyPaul van Trotsenburg, Athanasia Stoupa, Juliane Léger, et al.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal HyperplasiaRichard J Auchus, Oksana Hamidi, Rosario Pivonello, et al.
Clinical Endocrinology|October 24, 2020
Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohortNicolas Jullien, Alexandru Saveanu, Julia Vergier, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Journal of Clinical Medicine|January 21, 2022
A Tear Metabolomic Profile Showing Increased Ornithine Decarboxylase Activity and Spermine Synthesis in Thyroid-Associated OrbitopathyBenjamin Billiet, Juan Manuel Chao de la Barca, Marc Ferré, et al.
European Journal of Endocrinology|August 20, 2013
Surgery for 'asymptomatic' mild primary hyperparathyroidism improves some clinical symptoms postoperativelyClaire Blanchard, Muriel Mathonnet, Frédéric Sebag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)Alan L Ho, Marek Dedecjus, Lori J Wirth, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Lancet (London, England)|October 19, 2004
Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardationEdith C H Friesema, Annette Grueters, Heike Biebermann, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2020
Congenital Hypothyroidism: A 2020-2021 Consensus Guidelines Update-An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for EndocrinologyPaul van Trotsenburg, Athanasia Stoupa, Juliane Léger, et al.
The New England Journal of Medicine|June 3, 2024
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal HyperplasiaRichard J Auchus, Oksana Hamidi, Rosario Pivonello, et al.
Clinical Endocrinology|October 24, 2020
Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohortNicolas Jullien, Alexandru Saveanu, Julia Vergier, et al.
Pageof 9